SRF and prostate carcinoma: Some of the regulators affected by this treatment however could be implicated in anti-tumorigenic activities (i.e., IL-6 (Jiang et al., 2011)), yet modulation identified in other regulators are potentially implicated in prostate cancer tumorigenesis, such as BHLHE40 (Dmitriev et al., 2015), and SRF (Prencipe et al., 2018).